pre-update Archives

Knowledge Base

9 Frequently Misunderstood Concepts in PK/PD Modeling

In teaching pharmacometrics, I've noticed that scientists have difficulty with certain PK/PD modeling concepts. Maybe…

Nathan Teuscher2015年11月3日

Publication

Population PK & Dosing Implications for Cobimetinib in Cancer Patients

A population pharmacokinetic model was developed for cobimetinib in cancer patients. Covariates had minimal impact…

Danielle Pillsbury2015年11月1日

Publication

Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model

Bioavailability of orally administered drugs can be influenced by a number of factors including release…

Danielle Pillsbury2015年11月1日

Announcement

Introducing OpenCDISC Enterprise 3.0

Pinnacle 21 is proud to announce the launch of OpenCDISC Enterprise 3.0, which will be…

Certara2015年10月27日

Publication

Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-release Tablets to Elderly and Young Subjects

Tramadol is frequently used in geriatric patients; however, pharmacokinetic (PK) publications on tramadol and O-desmethyltramadol…

Danielle Pillsbury2015年10月27日

Publication

Development of a Multicompartment Permeability-limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs

Achieving sufficient concentrations of antituberculosis (TB) drugs in pulmonary tissue at the optimum time is still a challenge in…

Danielle Pillsbury2015年10月1日

Blog

How to Optimize Your Drug Label Using Modeling and Simulation Technology

As a trained pharmacist and scientist, I think a lot about patient care and how…

Certara2015年9月29日

Knowledge Base

9 Things Your Boss Wishes You Knew About PK/PD Modeling

Over the course of my career, I have taught the theory and practical applications of PK/PD…

Nathan Teuscher2015年9月15日

Publication

Modeling & Simulation Relating Survival to Tumor Growth Inhibition in Patients

The published OS model and resultant simulations can be leveraged to support Phase II design…

Danielle Pillsbury2015年9月1日

Publication

Are Physiologically-based Pharmacokinetic Models Reporting the Right Cmax? Central Venous Versus Peripheral Sampling Site

Physiologically based pharmacokinetic (PBPK) models can over-predict maximum plasma concentrations (Cmax) following intravenous administration. A proposed explanation is that invariably…

Danielle Pillsbury2015年9月1日

Powered by Translations.com GlobalLink Web Software

pre-update

9 Frequently Misunderstood Concepts in PK/PD Modeling

Population PK & Dosing Implications for Cobimetinib in Cancer Patients

Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model

Introducing OpenCDISC Enterprise 3.0

Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-release Tablets to Elderly and Young Subjects

Development of a Multicompartment Permeability-limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs

How to Optimize Your Drug Label Using Modeling and Simulation Technology

9 Things Your Boss Wishes You Knew About PK/PD Modeling

Modeling & Simulation Relating Survival to Tumor Growth Inhibition in Patients

Are Physiologically-based Pharmacokinetic Models Reporting the Right Cmax? Central Venous Versus Peripheral Sampling Site

メルマガ登録

クイックアクセス

ソリューション

お問合せ